Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Simvastatin stories

Nov 17, 2026

FDA proposes to withdraw approval for Salerno's liquid cholesterol medication

The FDA's drug evaluation department proposed withdrawing approval for Salerno Pharmaceuticals' liquid simvastatin oral suspension, citing missing annual reports.

Nov 17, 2026·3 sources
00

Top claims

  • ▪The U.S. Food and Drug Administration is offering Salerno Pharmaceuticals an opportunity for a hearing to argue why approval for FloLipid should not be withdrawn
  • ▪On November 17, 2026, the U.S. Food and Drug Administration drug evaluation department proposed withdrawing approval for Salerno Pharmaceuticals' FloLipid because Salerno repeatedly failed to submit required annual reports and respond to agency requests
  • ▪In 2020, the product label for FloLipid simvastatin oral suspension was updated to include a warning regarding rare reports of statin-associated immune-mediated necrotizing myopathy

Topics

StatinsFDA regulatory processLDL cholesterolDrug Policy, Pricing & Approval